28.49 USD
-0.03 (-0.11%)
28.49 USD
0 (0%)
Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 530 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making ALKS a very profitable company, without any liquidiy or solvency issues. ALKS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ALKS was profitable.
ALKS had a positive operating cash flow in the past year.
In multiple years ALKS reported negative net income over the last 5 years.
ALKS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ALKS has a better Return On Assets (14.57%) than 95.09% of its industry peers.
ALKS has a Return On Equity of 19.58%. This is amongst the best in the industry. ALKS outperforms 96.04% of its industry peers.
ALKS has a Return On Invested Capital of 16.22%. This is amongst the best in the industry. ALKS outperforms 96.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROIC | 16.22% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALKS has a better Profit Margin (22.30%) than 94.34% of its industry peers.
Looking at the Operating Margin, with a value of 23.59%, ALKS belongs to the top of the industry, outperforming 95.66% of the companies in the same industry.
ALKS's Gross Margin of 86.04% is amongst the best of the industry. ALKS outperforms 88.68% of its industry peers.
In the last couple of years the Gross Margin of ALKS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ALKS is creating value.
The number of shares outstanding for ALKS has been reduced compared to 1 year ago.
Compared to 5 years ago, ALKS has more shares outstanding
ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ALKS has an Altman-Z score of 6.08. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
ALKS has a Altman-Z score of 6.08. This is in the better half of the industry: ALKS outperforms 74.34% of its industry peers.
There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.08 |
ROIC/WACC2.1
WACC7.71%
2.3 Liquidity
ALKS has a Current Ratio of 3.67. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
ALKS's Current ratio of 3.67 is in line compared to the rest of the industry. ALKS outperforms 44.53% of its industry peers.
ALKS has a Quick Ratio of 3.27. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.27, ALKS is in line with its industry, outperforming 41.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.71% over the past year.
The Earnings Per Share has been growing by 32.50% on average over the past years. This is a very strong growth
The Revenue has been growing slightly by 1.08% in the past year.
The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
3.2 Future
Based on estimates for the next years, ALKS will show a decrease in Earnings Per Share. The EPS will decrease by -1.55% on average per year.
The Revenue is expected to grow by 7.72% on average over the next years.
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.49 indicates a reasonable valuation of ALKS.
Based on the Price/Earnings ratio, ALKS is valued cheaper than 97.17% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.57. ALKS is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 18.71 indicates a rather expensive valuation of ALKS.
ALKS's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALKS is cheaper than 94.72% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.04. ALKS is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.49 | ||
| Fwd PE | 18.71 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaply inside the industry as 97.55% of the companies are valued more expensively.
98.30% of the companies in the same industry are more expensive than ALKS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.58 | ||
| EV/EBITDA | 7.97 |
4.3 Compensation for Growth
ALKS has a very decent profitability rating, which may justify a higher PE ratio.
ALKS's earnings are expected to decrease with -19.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.35
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
5. Dividend
5.1 Amount
ALKS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
28.49
-0.03 (-0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.69%
Inst Owner Change8.97%
Ins Owners1.48%
Ins Owner Change-0.34%
Market Cap4.70B
Revenue(TTM)1.52B
Net Income(TTM)339.32M
Analysts80.87
Price Target44.75 (57.07%)
Short Float %11.63%
Short Ratio7.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)0.32%
PT rev (3m)4.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.27%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)17.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.41%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)3.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.49 | ||
| Fwd PE | 18.71 | ||
| P/S | 3.09 | ||
| P/FCF | 9.58 | ||
| P/OCF | 8.7 | ||
| P/B | 2.71 | ||
| P/tB | 2.85 | ||
| EV/EBITDA | 7.97 |
EPS(TTM)2.48
EY8.7%
EPS(NY)1.52
Fwd EY5.34%
FCF(TTM)2.98
FCFY10.44%
OCF(TTM)3.27
OCFY11.49%
SpS9.21
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.35
Graham Number24.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROCE | 19.34% | ||
| ROIC | 16.22% | ||
| ROICexc | 40.45% | ||
| ROICexgc | 45.58% | ||
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% | ||
| FCFM | 32.29% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 163.07% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 138.93% | ||
| Profit Quality | 144.77% | ||
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 6.08 |
F-Score6
WACC7.71%
ROIC/WACC2.1
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.47%
EBIT Next 3Y5.58%
EBIT Next 5Y14.79%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%
ALKERMES PLC / ALKS FAQ
What is the fundamental rating for ALKS stock?
ChartMill assigns a fundamental rating of 6 / 10 to ALKS.
What is the valuation status for ALKS stock?
ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.
Can you provide the profitability details for ALKERMES PLC?
ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.
What is the valuation of ALKERMES PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ALKERMES PLC (ALKS) is 11.49 and the Price/Book (PB) ratio is 2.71.
What is the expected EPS growth for ALKERMES PLC (ALKS) stock?
The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -48.04% in the next year.